Deals In Depth: October 2013
Eli Lilly agreed to co-promote Pfizer’s anti-NGF tanezumab for $200 million up front plus $350 million in regulatory milestones; private equity firms Avista and Nordic are taking Swiss pharmaco Acino private in a $439 million deal. Both biopharma and device financing increased in October vs. the previous month thanks to strong showings from IPOs and secondary offerings.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.